It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Changes in intestinal microecology during acute liver failure (ALF) directly affect the occurrence and development of the disease. The study aimed to investigate the relationship between the intestinal microbiota and the key immune cells. Fecal microbiota transplantation (FMT) was used to determine whether ALF can balance Th17/Treg cytokines. The relationship between gut microbiota and clinical indicators was analyzed. BALB/c mice were treated with d-galactosamine (d-GalN) to induce a murine ALF model. FMT to d-GalN mice was conducted to test for liver function indicators. Results showed that the proportions of Lachnospiraceae, Prevotella, S24-7, Odoribacter and Rikenellaceae in d-GalN mice with intestinal microbiota disorder were restored after FMT. Further, CIA analysis showed that bacteria had a covariant relationship with clinical indicators. Microbiota could account for changes in 49.9% of the overall clinical indicators. Adonis analysis showed that Ruminococcus, and Enterococcus have a greater impact on clinical indicators. FMT down-regulated the expression of IL-17A, TNF-α, and TGF-β, while up-regulated IL-10 and IL-22. Transplantation of feces from Saccharomyces boulardii donor mice improved GalN-induced liver damage. These findings indicate that FMT attenuates d-GalN-induced liver damage in mice, and a clinical trial is required to validate the relevance of our findings in humans, and to test whether this therapeutic approach is effective for patients with ALF.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Guizhou Medical University, Department of Medical Examination, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891); The Affiliated Hospital of Guizhou Medical University, Clinical Laboratory Center, Guiyang, China (GRID:grid.452244.1)
2 The Affiliated Hospital of Guizhou Medical University, Department of Infectious Diseases, Guiyang, China (GRID:grid.452244.1)
3 Peking University Health Science Center School of Foundational Education, Peking University, Department of Clinical Medicine, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)
4 Guizhou Maternal and Child Health Care Center, Guiyang, China (GRID:grid.11135.37)
5 The Affiliated Tumor Hospital, Guizhou Medical University, Deparment of Blood Transfusion, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891)
6 Prenatal Diagnosis Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China (GRID:grid.452244.1)
7 The Affiliated Hospital of Guizhou Medical University, Department of Blood Transfusion, Guiyang, China (GRID:grid.452244.1)
8 The Affiliated Hospital of Guizhou Medical University, Department of Respiratory, Guiyang, China (GRID:grid.452244.1)
9 The Affiliated Hospital of Guizhou Medical University, Clinical Laboratory Center, Guiyang, China (GRID:grid.452244.1)